摘要
SP600125是JNK激酶抑制剂,可特异性阻断JNK细胞转导通路,对缺血再灌注损伤起保护作用,并且抑制细胞活化和分化,相关炎症基因表达。笔者就SP600125抑制剂治疗脑、肝、心、肺、肾及脊髓缺血再灌注损伤的基础和实验研究成果做一综述,以期为临床医师选择使用SP600125抑制剂提供理论依据,同时提出在IRI中除了JNK信号通路影响之外是否存在诸如JAK-STAT、PI3K-Akt等信号通路,有可能成为临床治疗IRI新靶点。
SP600125 is JNK kinase inhibitors,specifically blocking JNK cell transduction pathway. Besides,it can protect ischemia-reperfusion injury（IRI） and inhibit cell activation and differentiation,inflammation related gene expression. In this review,authors summarize the relevant research results of SP600125 inhibitors in the treatment of brain,liver,heart,lung,kidney and spinal cord ischemia-reperfusion injury,so as to provide a theoretical basis for clinicians to choose the use of SP600125 inhibitors. At the same time,in addition to the effect of JNK signal pathway in IRI,it is suggested that whether there is a signal pathway,such as JAK-STAT and PI3K-Akt as well other signaling pathways may become a new target for clinical treatment IRI.
出处
《实用医药杂志》
2016年第4期360-362,366,共4页
Practical Journal of Medicine & Pharmacy
基金
安徽省自然科学基金项目(1408085MH202)
